Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL735732 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL10534546 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL6355287 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL275060 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL17941718 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL9306687 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL15353579 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL16755696 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL151048 | 1.00 | SLC34A1 (0.58) | — | |
| Phosphoric Acid SCHEMBL3178457 | 1.00 | SLC34A1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1077 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691496-A1 | PHARMACEUTICAL PREPARATION CONTAINING GLP-1 FUSION PROTEIN AND USE THEREOF | Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | PERIMETER SOLUTIONS, LP (US) | 2026-01-15 | — | — | US | claimed |
| WO-2025264733-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | PERIMETER SOLUTIONS, LP (US) | 2025-12-26 | — | — | WO | claimed |
| US-12377049-B2 | Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof | SHANGHAI BOCIMED PHARMACEUTICAL CO., LTD. (CN) | 2025-08-05 | — | — | US | claimed |
| EP-4099986-B1 | XANTHAN-BASED OPHTHALMIC TOPICAL FORMULATIONS WITH A REDUCED DOSAGE REGIMEN | SIFI SPA (IT) | 2025-06-04 | — | — | EP | claimed |
| US-20250171674-A1 | LIGHT-ABSORBING HEAT-STORAGE COMPOSITE MATERIAL AND PREPARATION METHOD THEREOF | SHANXI SANSHUI ENERGY CO LTD (CN) | 2025-05-29 | — | — | US | claimed |
| US-20250135254-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | FRS GROUP, LLC (US) | 2025-05-01 | — | — | US | claimed |
| CN-119842367-A | Hydrated salt phase-change gel material, wearable device and preparation method | 华南理工大学 | 2025-04-18 | — | — | CN | claimed |
| US-20250121235-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | FRS GROUP, LLC (US) | 2025-04-17 | — | — | US | claimed |
| CN-119818450-A | Pharmaceutical composition of levoketorolac and preparation method thereof | 南京海融医药科技股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-20090110716-A1 | ORALLY DISINTEGRATIVE DOSAGE FORM | MCNEIL-PPC, INC. | 2009-04-30 | — | — | US | claimed |
| CN-101316580-A | Fexofenadine suspension formulation | SANOFI AVENTIS US LLC (US) | 2008-12-03 | — | — | CN | claimed |
| US-20030187054-A1 | Preparations for chondrogenesis | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-02 | — | — | US | claimed |
| EP-1266664-A1 | PREPARATIONS FOR CHONDROGENESIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-18 | — | — | EP | claimed |
| EP-0777495-B1 | STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS | SCHERING CORP (US) | 2000-07-19 | — | — | EP | claimed |
| EP-0240635-B1 | PROCESS FOR THE MANUFACTURE OF DISODIUM PHOSPHATE | NEGEV PHOSPHATES LTD. (IL) | 1990-03-07 | — | — | EP | claimed |
| US-4759920-A | Process for the manufacture of disodium phosphate | NEGEV PHOSPHATES LTD. (IL) | 1988-07-26 | — | — | US | claimed |
| EP-0240635-A1 | Process for the manufacture of disodium phosphate | NEGEV PHOSPHATES LTD. (IL) | 1987-10-14 | — | — | EP | claimed |
| EP-0040654-B1 | ELECTROLYTE DRINK CONCENTRATE | VITAPHARM PHARMACEUTICAL PTY LTD. (AU) | 1984-04-18 | — | — | EP | claimed |
| US-3957501-A | SILICON, ALLOYS, WATER GLASS, FOAMING, CURING, COMPRESSION | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JA) | 1976-05-18 | — | — | US | claimed |